Abliva AB Interim Report January – March 2024
SEK 46 million raised through preferential rights issue | Preparations for the interim analysis ongoing
Press releases
Abliva AB Interim Report January – March 2023
Patient screening ongoing in the FALCON study | Orphan Drug Designation for NV354
Abliva AB Interim Report January – March 2022
First quarter summary
Abliva AB Interim Report January – March 2021
First quarter summary
Interim Report January-March 2020
Important events, first quarter (Jan – Mar 2020) NeuroVive proposes a 90 percent guaranteed rights issue of MSEK 74 in order to ensure that the Company has financial resources for […]
NeuroVive Pharmaceutical AB Interim Report January – March 2019
First subjects enrolled in the KL1333 study
NeuroVive Pharmaceutical AB Interim report January – March 2018
Successful rights issue
NeuroVive Pharmaceutical AB Interim report January – March 2017
Broadened project portfolio
NeuroVive: Interim Report 1 Jan. 2016 to 31 Mar. 2016
Full speed ahead First Quarter (1 Jan. 2016 – 31 Mar. 2016)Net revenues were SEK 0 (0) and other operating income was SEK 46,000 (49,000).Loss before tax was SEK 10,916,000 […]
NeuroVive: Interim report 1 Jan. 2015 till 31 Mar. 2015
Capital raising characterizes NeuroVive ́s first quarter
NeuroVive: Interim report 1 Jan. 2014 till 31 Mar. 2014
Successful rights issue and final patient treated in phase III study on CicloMulsion®
NeuroVive: Interim report 1 Jan. 2013 till 31 Mar. 2013
The listing on Nasdaq OMX creates possibilities for the future